Airway mucus hypersecretion contributes to the morbidity and mortality in patients with 24 chronic inflammatory lung diseases. Reducing mucus production is crucial for improving 25 patients' quality of life. The transcription factor SAM-pointed domain-containing Ets-like 26 factor (SPDEF) plays a critical role in the regulation of mucus production, and therefore 27 represents a potential therapeutic target. This study aims to reduce lung epithelial mucus 28 production by targeted silencing SPDEF using the novel strategy epigenetic editing. 29
Introduction 40
Airway epithelial mucus secretion and mucociliary clearance plays a key role in protective 41 innate immune responses against inhaled noxious particles and microorganisms. However, 42 excessive mucus production and secretion contributes to the pathogenesis of several 43 chronic inflammatory lung diseases such as asthma and chronic obstructive pulmonary 44 disease (COPD) (9, 11, 27) . In patients with asthma and COPD, mucus hypersecretion is 45 associated with cough and sputum production, respiratory infections, accelerated lung 46 function decline, exacerbations and mortality (23, 34) . Therefore, targeted treatment of 47 pathologic airway mucus secretion is expected to not only improve symptoms of cough and 48 dyspnea, but also decrease the frequency of disease-related exacerbations and decelerates 49 the disease progression. In the past few years, in preclinical models relevant to COPD, 50 several drugs were shown to reduce mucus hypersecretion (21) . However, none of these 51 drugs targeted the mucus producing cell itself. 52
Airway mucus contains mostly water and secreted mucins that contribute to the viscosity 53 and elasticity of mucus gels. Mucin 5AC (MUC5AC) is the major secreted mucin, which is 54 mainly produced by goblet cells in the airway epithelium. In chronic respiratory diseases, 55 mucus hypersecretion is highly associated with increased numbers of goblet cells, as well as 56 up regulated levels of mucin synthesis and secretion (9). SAM pointed domain-containing 57
Ets transcription factor (SPDEF) has been reported to be a core transcription factor (TF) that, 58 within a large network of genes, controls mucus production and secretion (6, 22, 35) . In 59 lung, SPDEF is selectively expressed in goblet cells lining the airways of patients with chronic 60 lung disease (6) and mice exposed to allergens (25) . In mice, the absence of SPDEF was 61 shown to protect from goblet cell development after allergen exposure (6, 26) . Moreover, 62 knockdown of SPDEF with small interfering RNA (siRNA) was found to significantly reduce 63 the expression of IL-13-induced MUC5AC expression and Anterior gradient 2 (AGR2) 64 expression, which encodes a potential chaperone required for mucin packaging, in the 65 human bronchial epithelial cell line 16HBE (36) . These observations suggest that SPDEF 66 could be a potential therapeutic target of airway mucus hypersecretion. In this study we set 67 out to silence SPDEF expression by epigenetic editing. Epigenetic editing is a novel approach 68 to modulate epigenetic states locally by targeting an epigenetic enzyme to the locus of 69 interest via DNA-targeting systems, such as zinc fingers (ZFs), transcription activator-like 70 effectors (TALEs), or clustered regularly interspaced short palindromic repeats (CRISPRs) (5, 71 8, 17, 33) . Compared to artificial transcription factors (ATFs), which exploit programmable 72 DNA-binding platforms to target transcriptional activators or repressors with no catalytic 73 domain (such as super KRAB Domain, SKD), epigenetic editing has the promise to induce 74 stable and inheritable gene modulation (4, 31) . In this study, we provide proof-of-concept 75 that SPDEF provides a promising target for epigenetic editing to prevent epithelial MUC5AC 76 expression. 77 78
Materials and Methods

79
Cell culture 80 Human bronchial epithelial 16HBE 14o-(16HBE) and BEAS-2B, mucoepidermoid carcinoma 81 NCI-H292 and type II alveolar carcinoma A549 cell lines were cultured as previously 82 described (15) . The human embryonic kidney HEK293T cell line (obtained from American 83 Type Culture Collection (ATCC)) and the breast cancer cell line MCF7 (obtained from ATCC: 84 HTB-22) were cultured in Dulbecco's modified Eagle medium (Biowhittaker, Verviers, 85 gentamicin, and 10% FBS (Biowhittaker) . 87
88
Plasmids Constructs
89
Four 18-bp zinc finger (ZF) protein target sites were selected within the SPDEF promoter 90 using the website www.zincfingertools.org., as previously described (16). The target 91 sequences are shown in Fig. 2a . The DNA sequences encoding the ZFs were synthesized by 92 Bio Basic Canada. The fragments encoding the ZFs were digested with BamHI/ NheI 93 restriction enzymes (Thermo Fisher Scientific, Carlsbad, USA) and cloned into a SKD-NLS-ZF-94 TRI FLAG backbone, which encodes SKD, a triple-FLAG tag and a nuclear localization signal 95 (NLS) or a ZF-NLS-VP64-TRI FLAG backbone, which encodes a tetramer of Herpes Simplex 96 Virus Viral Protein 16 (VP64). Then the SKD-NLS-ZF SPDEF-TRI FLAG fragments and the ZF 97 SPDEF-NLS-VP64-TRI FLAG were XbaI/ NotI (Thermo Fisher Scientific) digested and 98 subcloned into a dual promoter lentiviral vector pCDH-EF1-MCS-BGH PCK-GFP-T2A-Puro 99 (SBI, Cat. #CD550A-1), obtaining constructs CD550A-1 SKD-ZF SPDEF and CD550A-1 ZF 100 SPDEF-VP64. To obtain the constructs CD550A-1 ZF SPDEF-DNMT3A, the DNMT3A catalytic 101 domain (kindly provided by Dr. A Jeltsch) was digested out from pMX-ZF-DNMT3A-IRES-GFP 102 with AscI and PacI, to replace VP64 in the CD550A-1 ZF SPDEF-VP64 vector. Catalytically 103 mutant of DNMT3A (E74A) (13) was generated by PCR-mediated site directed mutagenesis 104 on CD550A-1 ZF SPDEF-DNMT3A. To obtain the constructs CD550A-1 ZF SPDEF-G9a and 105 CD550A-1 ZF SPDEF-G9a W1050A, the G9a catalytic domain and its mutant was digested out 106 from pMX-E2C-G9a and pMX-E2C-G9a W1050A (10) with AscI and PacI, to replace VP64 in 107 the CD550A-1 ZF SPDEF-VP64. To construct the CD550A-1 ZF SPDEF without effector domains (EDs) (SPDEF-NOED), VP64 in the CD550A-1 ZF SPDEF-VP64 was swapped out with 109 PCR by a multiple cloning site, including restriction sites for AscI, Nsil, BclI, SwaI, and PacI. 110 The primer information is presented in Table 1. pHAGE EF1α dCas9-VP64 lentiviral construct  111 was a gift from Rene Maehr & Scot Wolfe (Addgene plasmid # 50918)(18) and the single-112 chain guide RNA encoding plasmid MLM3636 was a gift from Keith Joung (Addgene plasmid 113 # 43860). An additional multiple cloning site was added by replacing the VP64 activator with 114 a sequence containing a MluI restriction site. To obtain the dCas9-epigenetic editor 115 constructs, the G9a catalytic domain and its mutant, the SUV39h1 catalytic domain (10), and 116 the catalytic domain of EZH2 (SET) and its mutant were digested out from pMX-ZF-IRES-GFP 117 with MluI and NotI and subcloned into the empty pHAGE EF1α dCas9. The SKD domain and 118 the DNMT3A3L catalytic domain and its catalytic mutant (29) were subcloned by amplifying 119 with primers containing MluI and NotI overhangs. Cloning of guide RNAs (gRNA) was 120 achieved as previously described (4). Briefly, pairs of DNA oligonucleotides encoding 20 121 nucleotide gRNA targeting sequences were annealed together to create double-stranded 122 DNA fragments with 4-bp overhangs. These fragments were ligated into BsmBI-digested 123 plasmid pMLM3636. Two gRNAs were designed to bind close to the region where ZF3 and 124 ZF4 bind ( Fig. 2A ) (GCATGGATCCCCCAGCAAGG and CCTCAGGTTGGGCCTTGCCA, 125 respectively) and a third gRNA was designed to bind just before transcription start site 126 (CTGGCCAACTCTTCATCTCG). We verified all constructs by DNA Sanger sequencing 127 (Baseclear, Leiden, the Netherlands). 128
Lentiviral transduction 130
The lentiviral CD550A-1 constructs, encoding the SPDEF targeting ATFs and epigenetic 131 editors, were co-transfected with the third generation packaging plasmids pMDLg/pRRE, 132 pRSV-Rev, pMSV-VSVG into HEK293T cells using the calcium phosphate transfection method 133 to produce lentiviral particles. The supernatant of HEK293T cells containing virus was 134 harvested at 48 and 72 hours after transfection. Host A549 cells were seeded in six-well 135 plates with a density of 80,000 cells per well and transduced on two consecutive days with 136 the viral supernatant, supplemented with 8 µg/mL polybrene (Sigma-Alrich, Zwijndrecht, 137 Netherlands). The positive transduced cells were selected in 8 µg/mL puromycin 138 supplemented medium for four days from 72h after the last transduction and then were 139 cultured in 1 µg/mL puromycin supplemented medium. Medium was refreshed every 2-3 140 days. Ten days after the last transduction, cells were harvested for western blot, as well as 141 RNA and DNA extraction. In the meantime, cells were grown on coverslips for 142 immunocytochemistry (IHC) and harvested for chromatin immunoprecipitation. Kinase Inhibitor 1A (CDKN1A) and beta-actin (ACTB) using SYBR® Green PCR Master Mix (Thermo Fisher Scientific) and gene-specific primers (Table 1) For DNA methylation analysis of the target regions, genomic DNA was extracted with 181 chloroform-isopropanol and was bisulfite converted using the EZ DNA Methylation-Kit 182 (Zymo Research), following the manufacturer's protocol. Bisulfite-converted DNA was 183 analyzed by pyrosequencing as previously described (7). The primer information for 184 pyrosequencing is presented in Table 1 . 185 186
Histone modification analysis by chromatin immunoprecipitation and qPCR 187
Histone modification induced by ZFs-G9a was analyzed by ChIP as previously described (12). 188
Briefly, A549 cells were fixed with 1% formaldehyde at 37 °C for 10 min and subsequently 189 lysed and sonicated using a Bioruptor (Diagenode; High, 30 sec on, 30 sec off, total time 15 190 minutes). Sheared chromatin was cleared by centrifuge at 4°C (12,000 × g, 10 minutes). Four 191 microgram of specific antibodies [normal rabbit IgG (abcam, ab46540), H3K9me2 (Milipore, 192 07-441)] were bound to 50 µl of magnetic Dynabeads (Thermo Fisher Scientific) during 15 193 minutes incubation, then unbound antibodies were washed-off. Sheared chromatin 0.25 194 million cells was added to the antibody precoated magnetic Dynabeads (rotating overnight at 4°C). Next day, the magnetic Dynabeads were washed three times with PBS, and 196 chromatin was eluted with 1% (w/v) SDS and 100 mmol/L NaHCO3. Subsequently, the 197 elutes were treated with RNase (Roche) for four hours and proteinase K (Roche) for one 198 hour at 62°C. Then, the column (Qiagen) purified DNA could be analyzed with quantitative 199
PCR (qPCR). 200
To assess the induction of histone marks and their spreading, several primer pairs were used 201 for the SPDEF promoter (Table 1) 
Detection of protein expression by western blot 207
Transduced A549 cells were lysed in RIPA buffer and proteins were analyzed by standard 208 western blotting as previously described (7). Then, the blots were incubated with a rabbit 209 anti-human SPDEF antibody (Santa Cruz, sc-67022), mouse anti-FLAG (Sigma, F3165) and 210 mouse anti-GAPDH (Santa Cruz, sc-47724) at 4°C, overnight, followed by incubation with an 211 horseradish peroxidase (HRP)-conjugated secondary goat anti-rabbit and rabbit anti-mouse 212 antibody (Dako, Glostrup, Denmark). Protein expression was visualized using the Pierce ECL2 213 chemoluminescence detection kit (Thermo Fisher Scientific) and Gel Doc™ XR+ imaging 214 systems (Bio-Rad Laboratories). Data were analyzed with Gel Doc™ XR+ Image Lab™ 215
software. 216
Immunocytochemistry 218 Cells grown on coverslips (Menzel-Gläser, 12 mm in diameter) were washed with PBS and 219 fixed with 2% (w/v) Paraformaldehyde for 20 min. Cells were stained with primary antibody 220 against MUC5AC (Abcam, ab3649), followed by HRP-conjugated secondary antibody. The 221 peroxidase was visualized by staining with AEC (3-amino-9 ethylcarbazole), followed by 222 hematoxylin counterstaining. The cover glasses were mounted with Kaiser's glycerol-gelatin 223 (37°C) and scanned into digital whole slides images using the NanoZoomer series scanning 224 devices. The assessment of immunochemistry staining intensity was performed 225 semiquantitatively in a blinded fashion at four to six of x20 magnification fields. MUC5AC 226 stained cells were categorized as follows: negative (no staining), weak-positive (pink color or 227 small red dot staining) and strong-positive (red staining and >50% of cell volume). 228 FLAG tagged proteins were stained with anti-FLAG antibody (Sigma, F3165), followed by 229 HRP-conjugated secondary antibody and AEC staining. FLAG stained cells were categorized 230 to negative and positive, and counted in a blinded fashion at four x20 magnification fields. 231 232 Statistics 233 All transduction experiments were performed at least three times independently. Data were 234 analyzed using one-way ANOVA followed by Bonferroni's Multiple Comparison Test. Data 235 were considered to be statistically significant if P<0.05. Data were expressed as mean ± SEM 236 and calculated using Prism v5.0 (GraphPad software). 237
Results
239
SPDEF down regulation by ATFs and subsequent repression of mucus-related genes 240
To select a suitable model to study SPDEF down regulation, SPDEF expression was 241 determined in four different human epithelial cell lines: A549, H292, A549 cells demonstrated the highest expression of SPDEF, both at mRNA level ( Fig. 1A) and 243 at protein level (Fig. 1B) 1D ). Differential expression of MUC5AC was consistent with the observed SPDEF 251 expression, with the highest MUC5AC expression in A549 cells (Fig. 1C ). To explore effective 252 SPDEF down regulation, we chose the highest SPDEF and MUC5AC expressing cell line 253 (A549) as a model. 254
In order to down regulate SPDEF expression, four ZFs were designed to bind 18-base pair 255 regions in the SPDEF promoter (SPDEF1, SPDEF2, SPDEF3, SPDEF4) and were sub-cloned into 256 lentiviral constructs containing SKD ( Fig. 2A ). A549 cells were transduced to express the ATF 257 using these lentiviral constructs. To enrich for cells expressing the ATF, the lentiviral 258 transduced cells were positively selected based on puromycin resistance. Correct size of 259
ATFs was confirmed by western blot (Fig. 2C ) and their nuclear location by 260 immunohistochemical staining (Fig. 3D ). FLAG positive cells ranged from 15% (SKD-SPDEF2) 261 to 64% (SKD-SPDEF3) after the selection with puromycin ( Fig 3D) . According to the FLAG 262 staining, SKD-SPDEF1 was expressed to a similar degree as SKD-SPDEF2, and both were 263 generally lower expressed than SKD-SPDEF3 and SKD-SPDEF4. 264 265 Next, we examined the ability of the four ATFs to down regulate SPDEF mRNA expression in 266 A549 cells. As shown in Fig. 2B , all four ATFs significantly down regulated SPDEF expression, 267 demonstrating 70, 97, 93, and 96% respectively down regulation relative to empty vector 268 control, which was confirmed at the protein level (Fig. 2C) . 269
As SPDEF regulates a network of genes associated with mucus production (2, 20, 28), we 270 investigated whether the down regulation of SPDEF expression mediated by ATFs indeed 271 resulted in reduced expression of mucus-related genes. Therefore, the expression level of 272 two downstream mucus-related genes was investigated in the ATF-expressing A549 cells. 273
We found that expression of AGR2 was significantly down regulated by SKD-SPDEF2 274 (90.9%±35.4% repression), SKD-SPDEF3 (79.3%±35.9% repression) and SKD-SPDEF4 275 (86.2%±35.4% repression) (Fig. 3A) . MUC5AC was consistently, yet not significantly, down 276 regulated in response to SPDEF repression (Fig. 3B ). However, MUC5AC immunochemistry 277 staining on ATF-transduced A549 cells supports successful inhibition at the protein level ( Fig.  278 3C and 3D). 279
SPDEF silencing by targeted epigenetic editing 280
In order to achieve the stable gene silencing, we set out to direct DNA methylation onto the 281 SPDEF promoter. As DNA methylation levels of CpG sites #13 (-3 bp), #14 (-1 bp) and #15 282 (+40 bp) around the TSS negatively correlated with SPDEF expression, ZF SPDEF3 targeting 283 location -131 to -114 bp was coupled to the catalytic domain of DNMT3A. To investigate the 284 induced DNA methylation in the promoter region of SPDEF, 15 CpG sites were screened with 285 pyrosequencing (Fig. 4) . We found that DNA methylation was induced on CpGs sites #14 and 286 15, and not on CpG sites #1-13. In further experiments, CpG sites #13-15 were analyzed. 287 SPDEF3-DNMT3A consistently deposited DNA methylation onto two CpG sites (CpG #14: 6.6 288 ± 0.8%; CpG #15: 10.5 ± 1.3%), compared with SPDEF3-NOED (CpG #site 14: 3.9 ± 0.3%; CpG 289 #15: 5.2 ± 0.8%) (Fig. 5B ). To determine whether the observed increase in DNA methylation 290 was directly caused by the catalytic activity of the DNMT3A enzyme, a catalytic mutant of 291 DNMT3A (DNMT3A E74A) was constructed and compared to DNMT3A in a separate set of 292 experiments. No increase in DNA methylation was observed for CpG sites #13-15 in SPDEF3-293 DNMT3A E74A treated cells (Fig. 5C ). To investigate whether the ZF directed DNMT3A was 294 able to reduce target gene transcription, SPDEF mRNA expression was investigated (Fig. 6A,  295 left panel). SPDEF3-DNMT3A was able to down regulate SPDEF expression (76.6%±25.5% 296 repression), which was equally efficient as repression induced by the positive control SKD-297 SPDEF3 (79.1%±12.7% repression). Interestingly, the construct that lacked the effector 298 domain, SPDEF3-NOED, also reduced SPDEF expression significantly (72.0%±25.3% 299 repression). To determine the influence of location, another ZF (SPDEF4: target sequence 300 +112 to +129) was tested to target DNMT3A to the SPDEF promoter. We found that SPDEF4-301 DNMT3A was able to better down regulate SPDEF expression (86.9%±12.1% repression) 302 than control SPDEF4-NOED (46.8%±35.1% SPDEF repression) and the catalytic mutant ( Fig.  303 6A), even though SPDEF4-DNMT3A didn't induce methylation changes in the investigated 304 region CpG13-15 ( Fig. 5D ). 305
Upon ZFs fused with the histone methyltransferase G9A, again, SPDEF4-G9A was able to 306 down regulate SPDEF expression equally efficiently as positive control SKD-SPDEF4 and 307 further repressed SPDEF expression than SPDEF4-NOED ( Fig. 6A ) However, no difference was detected between SPDEF4-G9A and its mutant and no H3K9me2 marks were detected 309 in the examined region (data not shown). The expression of the fusion proteins was 310 confirmed by the mRNA expression of the FLAG-tag (Fig. 7) . The SPDEF4-DNMT3A construct 311 was not higher expressed than its mutant, indicating that enhanced SPDEF repression of 312 SPDEF4-DNMT3A compared to its mutant was not because of more occupation of ZFs 313 SPDEF4 itself. 314 Down regulation of SPDEF by SPDEF3-DNMT3A, SPDEF4-DNMT3A, SPDEF3-G9A and SPDEF4-315 G9A was confirmed at the protein level by western blot (Fig. 8) . Importantly, expression of 316 downstream mucus related genes AGR2 and MUC5AC was also down regulated by these 317 constructs ( Fig. 6B and 6C) . 318
Lower number of strong MUC5AC positive cells after targeted silencing SPDEF by 319 epigenetic editing 320 The effect of SPDEF inhibition on mucus production was determined by quantification of the 321 number of MUC5AC positive cells. Transduced A549 cells were seeded on cover slips and 322 examined by immunochemistry staining. Interestingly, SPDEF silencing was most effective 323 within the MUC5AC strong positive cell population. Within this population, both SPDEF3-324 DNMT3A and SPDEF4-G9a treatment resulted in lower numbers of MUC5AC strong positive 325 ( Fig. 9B ). To rule out that the effects were caused by a general repressive effect of either 326 G9A or DNMT3A, we determined expression levels of four irrelevant genes (PLOD2, TP53, 327 RELA and CDKN1A) and found that none of these demonstrated inhibition of expression ( Fig.  328   10) . 329
Sustained epigenetic repression of SPDEF by epigenetic editing 331
To further address the effectiveness and sustainability of gene repression by epigenetic 332 editing, we decided to use the CRISPR-dCas9 system. We engineered stable MCF7 cell lines, 333 each one expressing dCas9 fusions either with the transcriptional repressor SKD, several 334 epigenetic editors or their mutants (G9a and SUV39h1 (for H3K9me), the SET domain of 335 EZH2 (for H3K27me), or a chimeric DNMT3a-DNMT3L fusion (for DNA methylation(30))). We 336 designed three gRNAs to bind around the promoter of SPDEF. By transiently transfecting a 337 mix of the three gRNAs into the stable cell lines, we were able to address the maintenance 338 of gene repression (Fig. 11A ). Gene repression was achieved to similar degrees two days 339 after transfecting the mix of gRNAs in all stable cell lines. As observed for ZF-fusions, 340 repression was also observed when using the mutant effector domains (Figs. 11 B-E) . 341 Importantly, for several other genes no such repressive effects by dCas9 without effector 342 domain have been observed in this stable system (data not shown). While repression by the 343 transcriptional repressor SKD and most of the epigenetic editors was not maintained, the 344 repression of SPDEF was sustained when using the G9a effector domain, while the mutant 345 fusion regained activation. 346
Discussion
347
Based on its important role in goblet cell differentiation and mucus production (6, 26), we 348 reasoned that SPDEF could be a suitable therapeutic target against mucus hypersecretion. In 349 this study, we were able to silence SPDEF expression in the human alveolar epithelial cell 350 line A549, using a novel strategy: engineered SPDEF targeting ZF proteins directing 351 transcriptional repressor (SKD), as well as epigenetic enzymes (DNMT3A and G9A). The 352 repression of SPDEF was accompanied by lower expression of mucus-related genes MUC5AC 353 and AGR2, as well as lower numbers of MUC5AC positive cells. 354
Our data provides an original proof-of-concept study supporting SPDEF as a promising 355 therapeutic target for inhibiting mucus production, which is amenable to stable repression 356 with epigenetic editing. As previously reported, knockdown of SPDEF using siRNA was able 357 to reduce the IL-13-induced expression of MUC5AC and AGR2 in human airway epithelial 358 16HBE cells (36). The principle of siRNA is to target and degrade mRNA. Because of the 359 constant production of mRNA, the silencing effect of siRNA is generally transient and it has 360 to be delivered repeatedly in clinical application. Epigenetic editing would be a superior 361 strategy because the effect would be sustained after clearance of the drug (hit and run 362 approach) (8). In order to down-regulate SPDEF expression directly at the transcriptional 363 level, four sequence-specific ZFs were generated. ZFs were first linked to SKD to test the 364 functionality of the DNA binding domain because SKD can cause transient gene silencing by 365 indirectly recruiting chromatin remodelers and histone-modifying enzymes (28, 32) . These 366 four ATFs (ZF-SKD) strongly reduced SPDEF expression and nearly abolished all expression of 367 SPDEF in A549 cells. More importantly, SPDEF silencing resulted in the additional down 368 regulation of MUC5AC mRNA and protein expression as well, indicating successful inhibition 369 of mucin synthesis. 370
Next, ZFs were fused to catalytic domains of epigenetic enzymes (DNMT3A and G9A), aiming 371 for longer term gene silencing by changing the epigenetic state of the targeted gene. ZF-372 targeted DNA methylation was recently successfully used for silencing several cancer-373 associated genes, including VEGF-A, SOXA2, and EpCAM (24, 28, 29, 31) . Here, we took 374 advantage of this approach by using two different ZFs engineered close to the TSS (SPDEF3 and SPDEF4), to down regulate SPDEF expression. In this area, high expression of SPDEF was 376 accompanied by lower DNA methylation of CpG sites, particularly those surrounding the 377 TSS, where DNA methylation is tightly linked to transcriptional silencing (3). The occlusion 378 binding of TF also explains our observation that ZFs without effector domains effectively 379 silenced SPDEF expression. We observed similar strong SPDEF repressive effects upon 380 targeting ZFs without any effector domain as upon targeting ZFs fused with repressor SKDs. 381
Many factors can explain the repressive effects of the binding of the gene targeting 382 constructs, like competition with endogenous transcription factors, such as SMAD, or 383 components of the preinitiation complex formation. Importantly, the effects were also 384 obtained when targeting CRISPR-dCas9 without an effector by the sgRNAs (20), indicating 385 that steric hindrance might indeed explain the repressive effect. Since such effects generally 386 are transient, it is important to assess that addition of domains to the targeting moiety do 387 not affect inhibition properties. Importantly, the fusion of effector domains to the ZFs did 388 not hamper the repressive effect of the ZF approach. 389
As the DNA binding domain by itself, or in fusion with SKD, is not expected to induce any 390 long-term effects, we next set out to test different epigenetic enzymes (DNMT3A and G9A). 391
Fusion of epigenetic effector domains with ZFs resulted in the same magnitude of silencing 392 as the ZF-SKD fusions, indicating that our approach worked as we aimed for. Furthermore, 393 targeted DNA methylation or histone methylation has the advantage that its effect has the 394 potential to be permanent (4, 28, 31), albeit the stability and heritability of epigenetic 395 editing is still controversial (14, 19) and likely depend on the local chromatin modification 396 state (4). 397
In an elegant experiment, Bintu and colleagues used an artificial system to compare four 398 repressive chromatin regulators with distinct chromatin modifications (2): the embryonic 399 ectoderm development (EED) protein of Polycomb repressive complex 2, which indirectly 400 catalyzes H3K27 methylation, the KRAB domain, that indirectly promotes H3K9 methylation, 401 the DNMT3B, that catalyzes DNA methylation and the histone deacetylase 4 (HDAC4) 402 enzyme. By transiently recruiting each protein, they demonstrate that different types of 403 repressed chromatin are generally associated with distinct time scales of repression. For this 404 artificial context, DNA methylation was the modification of choice to achieve long lasting 405 repression, while histone deacetylation was not sustained. Only few studies so far have 406 addressed stable silencing of endogenous genes, and controversial effects have been 407
reported (1, 19, 31) . Here, we provide indications that targeting epigenetic effector domains 408 to SPDEF has the ability to promote sustained gene expression reprogramming. Indeed, we 409 demonstrated that upon targeting G9A, maintenance of repression was obtained, which 410 was not observed for the transcriptional repressor SKD, DNA methyltransferase or other 411 histone modifiers. These differences in maintenance require more thorough investigations, 412 but likely are due to the particular local chromatin context of the targeted locus, that could 413 influence the potency and longevity of epigenetic reprogramming. This would also explain 414 the reported failure of maintenance of induced H3K9methylation effects when studying 415 VEGF-A repression (19) . Combining different effector domains, as we did previously for re-416 activation of gene expression, might further improve the degree of repression and/or 417 increase sustainability (4). Indeed, Amabile et al recently demonstrated the importance of 418 co-targeting KRAB, DNMT3A and DNMT3L in inducing maintained repression for 419 endogenous genes (1). 420
One limitation of our study is that functional experiments were conducted in the alveolar 421 cell line A549. Since we already showed convincing MUC5AC and AGR2 silencing in A549 422 cells, it will be interesting to investigate whether this effect is also observed within the more 423 relevant models of mucus hypersecretion in the future, such as using the air-liquid interface 424 culture of the primary airway epithelial cells from patients with COPD. In addition, before 425 use in the clinical setting, it is necessary to further evaluate the off-target effects, such as 426 the ZFs or CRISPR/dCas9 binding specificity and target cell specificity. 427
In summary, we successfully reduced mucus-related gene expression by targeted silencing 428 of SPDEF. This new approach (epigenetic editing) has the potential to induce a permanent 429 anti-mucus effect, which has implications for development of novel therapeutic strategies to 430 treat patients with chronic mucus hypersecretion in the future. right panels) to enlarge any difference between wild type and mutant effectors. Dot plots 511 represent the mean and variation of at least three independent experiments. Statistical 512 significance was analyzed using one-way ANOVA followed by Bonferroni's Multiple 513
Figure legends
Comparison Test (*P<0.05, **P<0.01, ***P<0.001, compared to empty vector; #P<0.05, 514 ##P<0.01, ###P<0.001, compared between two indicated columns). 515
Figure 7
Expression of ZF-ED after A549 cells treated with ZF fused to different effector 516 domain (SKD, DNMT3A, G9a, and respective mutant DNMT3A E74A and G9a W1050A). The 517 expression of ZF-ED was represented as the FLAG-tag expression relative to GAPDH (A), and 518 normalized to ZF-NOED (B and C). Dot plots represent the mean and variation of three 519 independent experiments. Statistical significance was analyzed using one-way ANOVA 520 followed by Bonferroni's Multiple Comparison Test (#P<0.05, ##P<0.01, ###P<0.001, 521 compared between two indicated columns). 522 
